NEUROONE MEDICAL TECHNOLOGIES Corp 8-K

What Happened NeuroOne Medical Technologies Corporation (NMTC) announced in an 8‑K filed June 12, 2026 that it filed an updated Prospectus under its Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC to offer and sell up to $13.4 million of its common stock (par value $0.001) in an "at‑the‑market" (ATM) program. The original Sales Agreement was entered December 21, 2022. Honigman LLP provided a legal opinion related to the Shares, which is attached as Exhibit 5.1 to the filing.

Key Details

• Updated Prospectus filed on June 12, 2026 for the ATM program.
• Authorization to offer up to $13.4 million of common stock through JonesTrading.
• Sales agent: JonesTrading Institutional Services LLC; program established under Dec 21, 2022 Sales Agreement.
• Shares to be sold pursuant to the company’s Registration Statement; offerings only by means of the Prospectus. Legal opinion from Honigman LLP attached.

Why It Matters This filing gives NeuroOne a ready mechanism to raise up to $13.4M over time by selling common shares into the market, providing financing flexibility without a single large underwritten offering. For investors, an ATM can be dilutive when shares are actually sold, and the filing does not mean shares will be sold immediately or at a specific price. The inclusion of counsel’s legal opinion and reliance on the company’s Registration Statement are routine steps to make the offering available when NeuroOne chooses to access the capital markets.